European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

46

PRINCETON, N.J.–European Commission Approves BMS’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia…

http://www.businesswire.com/news/home/20190211005351/en/European-Commission-Approves-Bristol-Myers-Squibb%E2%80%99s-Sprycel-dasatinib/